Close

BioArctic Receives Patent Protection in Japan for a Medical Device suffering with Spinal Cord Injury

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Omega Healthcare Expands Collaboration with Microsoft...

Omega Healthcare, a leading provider of technology-enabled RCM services,...

Haleon Breaks Ground on new £130m...

This week, Haleon, a global leader in consumer health...

Evonik Opens New Medical Device Center...

The company’s largest center for medical device applications,...

Johnson & Johnson Launches the Polyphonic...

Open call for innovation to help accelerate promising artificial...

BioArctic AB announced today that the Japanese Patent Office (JPO) issued a notification to grant the company’s patent application in Japan, 2014-545410, for a medical device, which is one of the main components in the product candidate SC0806.

The product candidate is a combination of a medical device (implant) and a medicinal product (FGF1) for patients with Complete Spinal Cord Injury. The notification states that the Japanese patent (derived from 2014-545410) will enter into force no later than April 13, 2018.

The patent will provide important protection for the medical device for treatment of patients with Complete Spinal Cord Injury. A corresponding patent has previously been granted in China and during 2018 also in Australia and the US.

“The patent protection is in line with the company’s strategy to protect important products through patents. A clinical Phase 1/2 study with the product candidate SC0806 for treatment of complete spinal cord injury is currently ongoing.

These patients lack effective treatment today. Our ambition is to develop SC0806 and improve the patients’ quality of life,” said Gunilla Osswald, CEO of BioArctic.

BioArctic has an active patent strategy covering all major geographic markets, including the US, EU, Japan and China.

Latest stories

Related stories

Haleon Breaks Ground on new £130m Global Oral Health Innovation Centre

This week, Haleon, a global leader in consumer health...

Evonik Opens New Medical Device Center in Shanghai

The company’s largest center for medical device applications,...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back